GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Vaxart Inc.
Vaxart is a biotech company developing oral (pill-based) vaccines. Its stock price is a bet on the success of its revolutionary delivery technology. The stock price reflects high volatility and reliance on clinical trial data.
Share prices of companies in the market segment - Pharma virus
Vaxart is a biotech company pioneering the development of oral vaccines that could replace traditional injections. We've categorized it under "Pharma: Viruses." The chart below shows how investors value innovative vaccine delivery platforms.
Broad Market Index - GURU.Markets
Vaxart is a biotech company pioneering the development of oral vaccines. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Vaxart's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
VXRT - Daily change in the company's share price Vaxart Inc.
For Vaxart, Inc., a company developing oral vaccines, daily volatility reflects sensitivity to clinical trial data. This metric is key to assessing the risks and prospects of its innovative platform.
Daily change in the price of a set of shares in a market segment - Pharma virus
Vaxart is a pioneer in the development of oral vaccines. The vaccine sector is highly volatile, and Vaxart's innovative approach offers both enormous potential and significant risks. The chart below reflects the average fluctuations in this industry, providing context for VXRT stock valuation.
Daily change in the price of a broad market stock, index - GURU.Markets
Vaxart is a pioneer in the development of oral vaccines in tablet form. This revolutionary company's shares reflect the high hopes and risks associated with the future of vaccination. Their high, speculative volatility is part of the dynamic of the innovation sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Vaxart Inc.
Vaxart, Inc.'s year-to-date performance is a story about the development of its unique oral vaccines. Its 12-month market cap depends entirely on clinical trial data. The success of its oral COVID-19 or flu vaccines could revolutionize vaccination, eliminating the need for injections, but biotech carries high risks.
Annual dynamics of market capitalization of the market segment - Pharma virus
Vaxart, Inc. is a biotechnology company developing unique oral (pill-based) vaccines. Its stock price is entirely speculative and is based on investors' belief in its ability to commercialize its breakthrough technology, not on current financial performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Vaxart, with its idea of vaccines in pills, is attempting to revolutionize the field. Its performance relative to the market is a pure venture bet on a technology platform. Success in clinical trials could make it a leader in the next generation of vaccines and lead to explosive share price growth.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Vaxart Inc.
Vaxart is a pioneer in the development of oral vaccines in tablet form. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its COVID-19 and influenza treatment programs are key events that generate strong reactions.
Monthly dynamics of market capitalization of the market segment - Pharma virus
Vaxart is a biotech company pioneering the development of oral vaccines delivered in pill form. This approach has the potential to revolutionize the vaccination process, making it simpler and more accessible. The graph below illustrates the dynamics of the biotech sector, where innovative delivery methods are a key competitive advantage.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Vaxart develops oral vaccines, making its stock a classic example of a biotech company. Its performance is completely disconnected from the market and driven by news about clinical trials. The chart clearly illustrates that for such companies, research data is more important than the overall economic situation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Vaxart Inc.
Vaxart, a pioneer in the development of oral vaccines, is experiencing extreme volatility. Weekly stock performance is driven by news about clinical trials, where any outcome could trigger a sharp reaction, reflecting hopes for a revolution in vaccination.
Weekly dynamics of market capitalization of the market segment - Pharma virus
Vaxart shares, like the entire biotech sector developing oral vaccines, are moving on the back of a general news cycle and expectations. Investor sentiment toward the entire concept is creating extreme volatility for everyone. The chart will show whether the company is leading the hype.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Vaxart develops oral vaccines. Its shares follow the rhythm of development news. The chart will show how VXRT's performance is independent of general market fluctuations, moving on its own unique scientific and commercial news.
Market capitalization of the company, segment and market as a whole
VXRT - Market capitalization of the company Vaxart Inc.
Vaxart's stock price is a financial bet on a revolution in vaccination. The market cap of this company, which develops pill-based vaccines, reflects the enormous hopes of eliminating injections. Its volatility directly mirrors the results of clinical trials, where every step could either bring a new era of vaccines closer or delay it indefinitely.
VXRT - Share of the company's market capitalization Vaxart Inc. within the market segment - Pharma virus
Vaxart is a pioneer in the development of oral tablet vaccines. The company's market capitalization in the biotech sector is a bet on revolutionizing vaccination. The company's size reflects hopes for a more convenient and affordable alternative to traditional injections, which could transform global healthcare.
Market capitalization of the market segment - Pharma virus
Vaxart is a pioneer in the development of oral (pill-based) vaccines. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect investors' hopes that this technology will make vaccination easier and more accessible.
Market capitalization of all companies included in a broad market index - GURU.Markets
Vaxart is a biotech company, a pioneer in the development of oral vaccines in tablet form. Its market capitalization chart is the story of a "vaccine without injections." Its volatile dynamics reflect the enormous potential of this idea and all the challenges associated with its clinical implementation.
Book value capitalization of the company, segment and market as a whole
VXRT - Book value capitalization of the company Vaxart Inc.
Vaxart develops oral vaccines. Its book value is represented by its capital and pilot production capacity. The chart below shows its financial and material resources for clinical trials. This is the story of an attempt to revolutionize vaccination.
VXRT - Share of the company's book capitalization Vaxart Inc. within the market segment - Pharma virus
Vaxart is a pioneer in the development of oral tablet vaccines. The company has its own manufacturing facilities, which is a key advantage. The asset share chart will show how its physical base enables it to control the production of future vaccines.
Market segment balance sheet capitalization - Pharma virus
Below you can see the overall book value of the pharmaceutical sector. Compared to this, Vaxart, which is developing oral vaccines, appears "easy" at the R&D stage. However, if the technology is successful, it will require massive investments in capital-intensive factories for mass production.
Book value of all companies included in the broad market index - GURU.Markets
Vaxart is a unique company developing oral (pill-based) vaccines. The company's assets are not its manufacturing plants, but its scientific platform and clinical trial data. The company's balance sheet is the value of its technology, which has the potential to radically change the physical reality of vaccination, eliminating the need for injections.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Vaxart Inc.
Vaxart's balance sheet is its cash and scientific platform. Its market capitalization is a speculative bet that its pill-based vaccine technology will one day work. The MvsBCap_Co chart shows how many times the "dream" of eliminating injections is worth compared to the company's actual cash.
Market to book capitalization ratio in a market segment - Pharma virus
Vaxart is developing a revolutionary technology for creating pill-based vaccines. Its value lies solely in this scientific potential. The chart shows the high speculative market valuation of its platform. The dynamics reflect not the asset price, but rather investors' hopes for the success of clinical trials.
Market to book capitalization ratio for the market as a whole
Vaxart is a biotech company developing oral vaccines. This is a revolutionary approach, and the company's market valuation depends entirely on the success of this idea. The chart shows the vast gap between its modest tangible assets and its market cap, built on investor expectations to disrupt the multibillion-dollar vaccine market.
Debts of the company, segment and market as a whole
VXRT - Company debts Vaxart Inc.
Vaxart, a company developing oral tablet vaccines, is using debt to finance its innovative platform. This chart shows how the company is raising capital to conduct clinical trials of its candidates, including those for influenza and COVID-19. The debt here is a bet on a more convenient and simpler vaccination method in the future.
Market segment debts - Pharma virus
Vaxart is a pioneer in developing oral (pill-based) vaccines that could revolutionize vaccination. This is a breakthrough technology, but its path to approval is long and expensive. This chart shows how a clinical-stage biotech company funds its innovative, yet risky and capital-intensive, research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Vaxart Inc.
Vaxart is developing innovative oral vaccines. This is a promising but risky technology. This chart shows the company's reliance on external funding to conduct expensive clinical trials. It reflects the company's high stakes that its unique approach to vaccination will prove successful and in demand.
Market segment debt to market segment book capitalization - Pharma virus
Vaxart is a biotech company developing oral vaccines, which could revolutionize vaccination. Clinical trials of this new technology are very expensive. The chart shows how the company's debt load relates to the market capitalization and risk of the entire biotech sector.
Debt to book value of all companies in the market
Vaxart (VXRT) is a pioneer in the development of oral (pill-based) recombinant vaccines. This approach is innovative but risky. This chart shows the overall level of debt in the economy. It clearly demonstrates why companies like Vaxart, offering breakthrough technologies, are financed through equity rather than bank loans.
P/E of the company, segment and market as a whole
P/E - Vaxart Inc.
This metric for Vaxart, a company developing oral vaccines, is a measure of faith in its unique technology. There is no P/E ratio. The company's valuation soared during the pandemic on hopes for a COVID-19 pill. Now its value depends on the success of vaccine development for other diseases, such as influenza.
P/E of the market segment - Pharma virus
This chart shows the average P/E valuation for biotech companies. For Vaxart, with its oral vaccine technology, it serves as a backdrop. It shows the overall level of investor faith in innovative vaccine platforms, providing context for Vaxart's valuation, which is a bet on its unique delivery method.
P/E of the market as a whole
Vaxart is a biotech company pioneering the development of oral vaccines. This technology has the potential to revolutionize vaccination. This chart shows the sentiment in the biotech industry. It helps us understand whether the market believes Vaxart can prove the efficacy and safety of its platform, and what potential it sees in this breakthrough, yet unproven, technology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Vaxart Inc.
Vaxart is developing oral tablet vaccines that could become a convenient alternative to injections. The company's future profitability depends entirely on the success of its clinical trials. This chart reflects analysts' speculative expectations regarding this innovative technology and its potential to transform the vaccine market in the future.
%20P%2FE%20Vaxart%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Vaxart-Inc.&v=1772625788339 "Chart of the company's future (projected) P/E Vaxart Inc.")
Future (projected) P/E of the market segment - Pharma virus
Vaxart, Inc. is a pioneer in the development of oral vaccines in tablet form. This chart shows average expectations for the biotech sector. VXRT's position may indicate the extent to which investors believe in its revolutionary technology, which could change the way vaccinations are administered, and in the success of its clinical programs, particularly against influenza and COVID-19.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772625788375 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
Vaxart is developing oral vaccines. This is an innovative approach that could change the market. The company's success depends on the results of clinical trials. Overall investor sentiment on this chart influences its valuation, but the technology and trial data are what truly matter.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772625788381 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Vaxart Inc.
Vaxart, Inc. is a biotechnology company developing oral recombinant vaccines in pill form. This graph illustrates the potential revolution in vaccination. The losses reflect the costs of clinical trials, while future profits depend on the success of their technology, which could eliminate the need for injections.
Profit of companies in the market segment - Pharma virus
Vaxart, Inc. is a pioneer in the development of oral (pill-formed) recombinant vaccines. Profitability in the antiviral drug sector, as this chart shows, can be transformed by new delivery methods. VXRT's success in creating an effective pill-formed vaccine could revolutionize logistics and the vaccination process, making it simpler and more accessible.
Overall market profit
Vaxart, Inc. is a biotech company developing oral (pill-based) vaccines. This innovative approach relies on clinical trial results rather than the economic cycle phase shown by this chart. However, major events such as pandemics can sharply increase investor interest and accelerate development.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Vaxart Inc.
Vaxart is a pioneer in the development of oral (pill-based) vaccines. This chart shows analysts' forecasts for future profits, which are a bet on the success of its revolutionary technology. It represents the financial expression of the hope that its developments will change the way vaccinations are administered in the future.
%20profit%20of%20the%20company%20Vaxart%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Vaxart-Inc.&v=1772625788636 "Graph of future (projected) profit of the company Vaxart Inc.")
Future (predicted) profit of companies in the market segment - Pharma virus
Vaxart, Inc. is a pioneer in the development of oral (pill-based) recombinant vaccines. This approach has the potential to revolutionize vaccination, making it simpler and more accessible. This chart shows the revenue forecast for the vaccine sector, reflecting the hopes for innovative platforms that could revolutionize infectious disease prevention.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772625788641 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
Vaxart develops oral vaccines. Like other biotech companies, its success depends on clinical trial results, not the economic outlook. However, the overall profit forecast is important for assessing the investment climate. During market downturns, raising funds for risky projects becomes more challenging.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772625788669 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Vaxart Inc.
Vaxart is a biotech company developing unique oral vaccines. It has no commercial products or revenue. The chart reflects the enormous bet investors are making on its revolutionary technology. The valuation is based on the potential to transform the way the world administers vaccines, making them simpler and more accessible, rather than on current financial performance.
P/S market segment - Pharma virus
Vaxart, Inc. is a pioneer in the development of oral recombinant vaccines in tablet form that could replace traditional injections. The chart shows the average revenue estimate for the biotech company, allowing one to estimate the premium investors are willing to pay for its potentially revolutionary vaccine delivery technology.
P/S of the market as a whole
Vaxart, Inc. is a biotech company developing oral vaccines in pill form that could replace injections. This technology has the potential to revolutionize vaccination. The graph of average market revenue estimates clearly shows that investors are buying not current revenues, but the potential for global change in healthcare.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Vaxart Inc.
Vaxart is a biotech company pioneering the development of oral vaccines. The chart illustrates the market's bet on this revolutionary technology. The company is valued based on the potentially huge future revenues its oral vaccines could generate, revolutionizing the vaccination process.
%20P%2FS%20Vaxart%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Vaxart-Inc.&v=1772625788767 "The graph of the company's future (projected) P/S Vaxart Inc.")
Future (projected) P/S of the market segment - Pharma virus
Vaxart, Inc. is a pioneer in the development of oral tablet vaccines that could replace traditional injections. This figure shows the median future revenue estimates for pharmaceutical companies. This helps gauge how highly investors value the revolutionary potential of Vaxart's platform and its potential to transform the vaccine market if successful.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772625788786 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
Vaxart, Inc. is a pioneer in the development of oral (pill-formed) vaccines. This is a revolutionary technology. This graph of overall revenue expectations is irrelevant. VXRT's entire value lies in the success of its scientific platform. The approval of one such vaccine could completely change the market and the company's fate, regardless of the state of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772625788855 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Vaxart Inc.
Vaxart is a pioneer in the development of oral tablet vaccines, which could significantly simplify vaccination. Currently in clinical trials, the company has no sales revenue. Revenue in this chart, if any, likely represents grants or payments from partners supporting its innovative platform.
Sales of companies in the market segment - Pharma virus
Vaxart, Inc. is a biotechnology company pioneering the development of oral vaccines in tablet form. This approach could significantly simplify vaccination by eliminating the need for injections and cold chain management. This chart shows the sector's total revenue, reflecting the search for and commercialization of new, more convenient vaccine delivery technologies.
Overall market sales
Vaxart is a biotech company developing oral vaccines. Its market capitalization depends on the success of clinical trials of its innovative platform. The overall economic situation, reflected in this chart, influences investor willingness to finance risky but promising biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Vaxart Inc.
Vaxart is a biotech company pioneering the development of oral tablet vaccines. Its future depends on the success of this user-friendly technology in clinical trials against various viruses. This chart reflects market expectations regarding this potential revolution in vaccination.
%20sales%20of%20the%20company%20Vaxart%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Vaxart-Inc.&v=1772625788899 "Schedule of future (projected) sales of the company Vaxart Inc.")
Future (projected) sales of companies in the market segment - Pharma virus
Vaxart is a pioneer in the development of oral (pill-based) vaccines. This formulation could radically change the vaccination process, making it simpler and more accessible. The graph shows forecasts for the antiviral pharmaceutical segment. If Vaxart's technology proves effective, it could become a true breakthrough in medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772625788903 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
Vaxart is developing oral (pill-formed) recombinant vaccines. The success of this innovative technology depends on the results of clinical trials and its ability to compete with traditional injections. This schedule, reflecting the overall economic situation, influences the amount of public and private funding for the development of new vaccine platforms.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772625788984 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Vaxart Inc.
Vaxart is a biotech company pioneering the development of oral vaccines in pill form. This could revolutionize vaccination, but it requires massive investment in research. This chart illustrates the financial costs involved in developing this breakthrough technology, which has the potential to be highly profitable.
Market segment marginality - Pharma virus
Vaxart is a pioneer in the development of oral tablet vaccines. This chart shows the average profitability in the pharmaceutical industry. This revolutionary delivery method, which could eliminate the need for injections, offers the company the potential to achieve exceptional profitability if its technology proves effective and safe.
Market marginality as a whole
Vaxart, Inc. is a biotechnology company developing oral (pill-formed) recombinant vaccines. This innovative technology has the potential to revolutionize vaccination. Currently in clinical trials, Vaxart demonstrates the long road from scientific idea to profitable product, as reflected by its average corporate profitability.
Employees in the company, segment and market as a whole
Number of employees in the company Vaxart Inc.
Vaxart is a pioneer in the development of oral tablet vaccines. This innovative technology has the potential to transform the way vaccinations are administered. This chart shows the size of the team of scientists and clinical trial specialists working to prove the efficacy and safety of this promising platform.
Share of the company's employees Vaxart Inc. within the market segment - Pharma virus
Vaxart is a pioneer in the development of oral vaccines in tablet form, which could radically change the way vaccinations are delivered. This is a breakthrough technology. The company's clinical trial team consists of exceptional scientists. This chart shows the proportion of specialists in the field of oral vaccine delivery that Vaxart has, reflecting its technological leadership.
Number of employees in the market segment - Pharma virus
Vaxart, Inc. is a biotechnology company pioneering the development of oral recombinant vaccines in tablet form. The growth of its scientific and clinical teams, visible in the graph, is directly related to progress in clinical trials. This increase in staffing indicates active work on several programs, including an influenza vaccine.
Number of employees in the market as a whole
Vaxart is a pioneer in the development of oral vaccines in tablet form, which could change the way vaccinations are administered. The growth of its scientific and clinical trial team in this chart reflects progress in this breakthrough field. This team expansion signals that the company is approaching key data points on its innovative platform.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Vaxart Inc. (VXRT)
Vaxart is a biotech company pioneering the development of oral (pill-based) vaccines. This is a revolutionary technology. Their market capitalization reflects investors' bet that their platform will transform the market. This metric demonstrates the enormous value the market attributes to this intellectual property per scientist working on it.
%20of%20the%20company%20Vaxart%20Inc.%20(VXRT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Vaxart-Inc.-VXRT&v=1772625789293 "Chart of market capitalization per employee (in thousands of dollars) of the company Vaxart Inc. (VXRT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
Vaxart is a pioneer in the development of oral vaccines. This revolutionary technology places all its value in research and patents, not in staff. This chart shows how highly investors value the company's intellectual capital and its unique platform per scientist.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772625789305 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
Vaxart develops oral (pill-formed) recombinant vaccines. The chart illustrates the valuation of this breakthrough vaccine delivery technology. The very high market capitalization per employee reflects the revolutionary potential of their platform, which could simplify and reduce the cost of mass vaccination on a global scale.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772625789393 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Vaxart Inc. (VXRT)
Vaxart is a biotech company trying to revolutionize the field by creating "pill-based" (oral) vaccines. The company is profitless. This chart shows the net loss (R&D costs) per scientist working on this "holy grail" of vaccinology.
%20Chart%20Vaxart%20Inc.%20(VXRT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Vaxart-Inc.-VXRT&v=1772625789415 "Company Profit Per Employee (in thousands of dollars) Chart Vaxart Inc. (VXRT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
Vaxart is a biotech company developing unique oral (pill-based) recombinant vaccines. This could radically change the way vaccinations are administered. This graph shows the loss per employee during the R&D phase. It serves as a benchmark for assessing how intensively Vaxart is investing in validating its breakthrough, but not yet commercially proven, platform.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772625789438 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
Vaxart is a biotech company developing a unique technology for oral (pill-based) vaccines, including for influenza and COVID-19. The company is in the R&D stage and is not profitable. This graph shows a negative value—the investment (loss) per scientist working on non-injectable vaccines.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772625789447 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Vaxart Inc. (VXRT)
Vaxart, Inc. develops oral (pill-based) vaccines. For the biotech company, this graph will reflect the monetization of its unique platform. Increased revenue per employee will likely result from a partnership with a major pharmaceutical company for further vaccine development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Vaxart-Inc.-VXRT&v=1772625789466 "Sales chart per company employee Vaxart Inc. (VXRT)")
Sales per employee in the market segment - Pharma virus
Vaxart (VXRT) is a biotech company developing unique oral vaccines. They made a significant impact during the pandemic, but they don't yet have an approved product. This graph doesn't reflect their value. The company has no commercial revenue, and staff productivity will be zero. The company is banking entirely on the success of their R&D platform.
Sales per employee for the market as a whole
Vaxart is a biotech company developing a unique platform of oral (pill-based) vaccines. At the R&D stage, this metric reflects investment in science. A team of scientists is working on breakthrough technology. This graph is an indicator of the future: if successful, it will demonstrate the enormous leverage of their intellectual property.
Short shares by company, segment and market as a whole
Shares shorted by company Vaxart Inc. (VXRT)
Vaxart (VXRT) is a biotech company with a unique idea: vaccines in pill form, not shots. Their platform is aimed at developing oral vaccines (for flu and COVID). This chart shows bearish bets. Bears doubt that oral vaccine delivery can be effective at all and believe their trials are doomed to failure.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Vaxart-Inc.-VXRT&v=1772625789594 "Short Shares Chart for the Company Vaxart Inc. (VXRT)")
Shares shorted by market segment - Pharma virus
Vaxart (VXRT) is a biotech company developing unique oral vaccines. Their goal is to replace injections with a more convenient form. This chart shows the overall bearish sentiment across the vaccine development sector. High values indicate that investors are generally skeptical of the sector, possibly following the pandemic's abatement or due to the high risk of clinical failure, which creates a backdrop for VXRT.
Shares shorted by the overall market
Vaxart is a biotech company chasing the "holy grail" of pill-based vaccines. It's a speculative R&D story. This chart illustrates the overall market pessimism. When fear reigns, investors are reluctant to finance a cash burn. They sell off shares of pre-profitable companies like VXRT, fearing they'll run out of money for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Vaxart Inc. (VXRT)
Vaxart (VXRT) is a pioneer in developing oral vaccines, including for COVID-19 and influenza. This technology is attracting a lot of attention. This oscillator measures the strength of speculative moves. It shows when the stock is "overheated" (above 70) on trial news or "oversold" (below 30) when there is no trial news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Vaxart-Inc.-VXRT&v=1772625789762 "RSI 14 indicator chart for the company's stock Vaxart Inc. (VXRT)")
RSI 14 Market Segment - Pharma virus
Vaxart is a "pill" instead of a shot. They are *pioneers* in the development of *oral* (in tablets) *vaccines* (for COVID, flu, norovirus). The "Pharma virus" (biotech/vaccines) sector thrives on news. RSI_14_Seg shows the "temperature" of *the entire* segment. It helps us understand: is VXRT's growth due to their R&D, or is *the entire* biotech "overheated"?
RSI 14 for the overall market
Vaxart (VXRT) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VXRT (Vaxart Inc.)
Vaxart is a biotech company developing a revolutionary platform of oral (pill-based) vaccines, including those for influenza and norovirus. This chart shows the average target price. Analysts' forecasts are based solely on clinical data, the likelihood of FDA approval, and the potential of this technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VXRT-Vaxart-Inc.&v=1772625789911 "A chart showing analyst consensus forecasts for the expected stock price. VXRT (Vaxart Inc.)")
The difference between the consensus estimate and the actual stock price VXRT (Vaxart Inc.)
Vaxart is a biotech company that wants to "kill the needle." Their R&D platform is aimed at developing oral (pill-based) flu and COVID vaccines. This chart measures the gap between the current share price and the consensus target price. It shows the enormous, yet risky, potential analysts see in this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VXRT-Vaxart-Inc.&v=1772625789960 "A chart showing the difference between the consensus forecast and the actual stock price. VXRT (Vaxart Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
Vaxart (VXRT) is a biotech company trying to create the "Holy Grail" of vaccines—a pill. Its R&D platform is focused on oral vaccines (for flu and COVID). This chart shows the general expectations of analysts in the pharmaceutical sector. It reflects whether experts believe in this revolutionary, but risky, delivery technology.
Analysts' consensus forecast for the overall market share price
Vaxart (VXRT) is a biotech company with a revolutionary idea: vaccines in pill form. Their platform aims to create oral vaccines (for flu and COVID) that eliminate the need for injections. This chart shows the overall risk appetite in the market. It reflects the willingness of investors to invest in breakthrough, yet still speculative, R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Vaxart Inc.
Vaxart is a biotech R&D company waging war on the needle. Their signature feature is the world's only R&D platform for oral (pill-based) vaccines (for COVID and flu). It's the Holy Grail of vaccination. This chart is a pure R&D barometer. It doesn't reflect sales (there aren't any), but rather a speculative assessment of their (very risky) clinical data and their race to keep up the good work.
AKIMA Market Segment Index - Pharma virus
Vaxart (VXRT) is a viral pharma with a revolutionary idea: a vaccine in pill form. They aim to replace injections with oral administration (for flu and Covid). This is the Holy Grail of R&D. This chart compares their composite index to the sector, showing how far their pill-based R&D platform outpaces their needle-based competitors.
The AKIM Index for the overall market
Vaxart is a biotech company developing oral vaccines (pills) for influenza, norovirus, and COVID-19. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this technology platform, which promises to simplify vaccination, compares to overall economic trends and interest in infectious diseases.
